Newly approved head and neck cancer treatment improves care for first time in more than 20 years
Newly approved head and neck cancer treatment improves care for first time in more than 20 years. https://pharmaceutical-journal.com/article/news/newly-approved-head-and-neck-cancer-treatment-improves-care-for-first-time-in-more-than-20-years
Busting Myths About Head and Neck Cancers
Are young people safe from these cancers? Are they always caused by smoking? What about mouthwash and cell phones? CU Anschutz expert Carissa Thomas, MD, PhD, FACS, sets the record straight. https://news.cuanschutz.edu/cancer-center/thomas-head-neck-cancer-myths
Immunotherapy Success Rate for Head and Neck Cancer: What Patients Need to Know In 2025
https://oncodaily.com/oncolibrary/immunotherapy-success-rate-for-head-and-neck-cancer
Image from
https://www.facebook.com/gevorg.tamamyan. (2025, December 14). Immunotherapy Success Rate for Head and Neck Cancer: What Patients Need to Know In 2025 - OncoDaily. Oncodaily - Oncology News, Insights, Stories. https://oncodaily.com/oncolibrary/immunotherapy-success-rate-for-head-and-neck-cancer
Circulating cell free HPVDNA in HPV positive head and neck cancer reveals fast responders and early peakers during treatment
https://www.nature.com/articles/s41598-025-33345-4
Google. (2026, January 21). Image generation for AMR Detection Article [Generative AI chat]. Gemini 2.5 Flash. https://gemini.google.com/share/2dad0d700fbc
NHS to fast-track patients with head and neck cancer into cancer vaccine trial
Patients with advanced head and neck cancers in England will be fast-tracked into a trial of a new cancer vaccine, as the NHS expands its world-leading trial ‘match-making’ service.
The investigational cancer vaccine uses mRNA technology to help the immune system recognise and kill cancer cells containing human papillomavirus proteins.
More than 100 patients with advanced head and neck cancer in England will be matched to the trial, running at 15 NHS hospitals over the next year, supported by the NHS’ Cancer Vaccine Launch Pad (CVLP).
This is the third cancer vaccine trial to be run through the NHS Cancer Vaccine Launch Pad, coordinated by the Southampton Clinical Trials Unit, which has already helped refer around 550 patients to trials of vaccines for bowel and skin cancers.
The first head and neck cancer patients in England have received the investigational mRNA cancer vaccine in the clinical trial, known as AHEAD-MERIT (BNT113-01), with more patients to soon be enrolled at their nearest NHS hospital.
More than 11,000 new head and neck cancer cases are diagnosed in England every year, with cancers typically developing in the mouth, throat or voice box.
Cutting-edge proton beam therapy is no better than advanced radiotherapy for treating head and neck cancer
Cutting edge proton beam therapy is no better than intensity-modulated radiotherapy for treating people with head and neck cancer, according to new research.
The nationwide TORPEdO trial funded by Cancer Research UK and The Taylor Family Foundation compared two forms of highly targeted radiotherapy for head and neck cancer – proton beam therapy (PBT) and intensity-modulated radiotherapy (IMRT).
Presented at the American Society of Radiation Oncology (ASTRO) Annual Meeting in San Francisco, California, the initial results of this multi-centre trial, sponsored and managed by The Institute of Cancer Research, London, found that there was no need for PBT for most people with head and neck cancer. Similar levels of side-effects from the treatment were observed in both groups.
PBT directs a beam of highly charged particles called protons onto a tumour to destroy the cancerous cells. IMRT uses advanced computer programmes to create a beam of radiation that matches the shape of a patient’s tumour, which the computer then directs onto the tumour using a machine called a linear accelerator (LINAC).
